Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.15B | $919.12M | $2.13 |
| 2024 | $10.38B | $1.00M | $0.00 |
| 2023 | $11.66B | $89.99M | $0.21 |
| 2022 | $9.30B | $847.75M | $1.97 |
| 2021 | $9.62B | $907.82M | $2.11 |
Social Signal Score
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SDZNY's reported EPS growth of 0.2% a year over 4 years.
- EPS in 5 years
- $2.15
- Implied price
- $73.21
- Return from $89.81
- -4.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $36.40 — -59.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 24 | 29 | 34 | 39 | 44 |
|---|---|---|---|---|---|
| -9.8% | -19.4% | -16.3% | -13.6% | -11.2% | -9.0% |
| -4.8% | -14.9% | -11.7% | -8.8% | -6.3% | -4.0% |
| 0.2% | -10.5% | -7.0% | -4.0% | -1.3% | 1.1% |
| 5.2% | -6.0% | -2.4% | 0.8% | 3.6% | 6.1% |
| 10.2% | -1.5% | 2.3% | 5.6% | 8.5% | 11.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newsprnewswire.com·6h ago·Negative
…RNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.
View source ↗ - Newsreuters.com·7h ago·Negative
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.
View source ↗